Pharmaceutical formulations
AssigneeSmithKline Beecham Corporation
InventorsArup K. Roy, Lloyd Gary Tillman
Life of this patent
Estimating the term…
Abstract
Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (alternatively known as VX 478 or 141W94), and a tocopherol, and their use in medical therapy are described.
Claims21
A pharmaceutical formulation possessing unexpectedly enhanced bio-availability, comprising:
- a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
- b) a water soluble tocopherol derivative, and
- (c) a hydrophilic non-aqueous solvent miscible with said water soluble tocopherol derivative.
A pharmaceutical formulation, comprising:
- a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl) propyl]carbamic acid, tetrahydro-3-furanyl ester,
- b) from about 10% to about 60% w/w of a water soluble tocopherol derivative, and
- (c) a hydrophilic non-aqueous solvent miscible with said water soluble tocopherol derivative,
- wherein the ratio of (a) to (b) is from about 1:0.5 to about 1:10 w/w, and wherein said formulation possesses unexpectedly enhanced bioavailability.
A pharmaceutical formulation, comprising:
- (a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
- (b) Vitamin E-TPGS,
- (c) polyethylene glycol, and
- (d) propylene glycol, and
- wherein said formulation possesses unexpectedly enhanced bioavailability.
A pharmaceutical formulation, comprising:
- (a) 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester in an amount from 1% to 50% w/w;
- (b) a water soluble tocopherol derivative in an amount from about 10% to about 60% w/w;
- and
- (c) a hydrophilic non-aqueous solvent miscible with the water soluble tocopherol derivative in an amount from about 15% to about 95%,
- wherein, the hydrophilic non-aqueous solvent is a polyethylene glycol, propylene glycol, polyvinyl pyrrolidone, or a combination thereof;
- and
- wherein said formulation possesses unexpectedly enhanced bioavailability.
A pharmaceutical formulation for oral administration, comprising:
- (a) about 19% w/w of 3S-[3R*(1R*,2S*)]-[3-[[4-aminophenyl)sulphonyl](2-methylpropyl)-amino]-2-hydroxy-1-phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester,
- (b) about 51% w/w of Vitamin E-TPGS,
- (c) about 25% w/w of polyethylene glycol, and
- (d) about 5% w/w of propylene glycol, and
- wherein said formulation possesses unexpectedly enhanced bioavailability.
Dependencies are inferred from the claim text.